NasdaqGS:COLLPharmaceuticals
Collegium Pharmaceutical (COLL) Margin Compression To 8.1% Tests Bullish Profitability Narrative
Collegium Pharmaceutical (COLL) has wrapped up FY 2025 with fourth quarter revenue of US$205.4 million and basic EPS of US$0.54, capping a year in which trailing 12 month revenue reached US$780.6 million and EPS came in at US$1.98. Over the last six reported quarters, revenue has moved from US$159.3 million in Q3 2024 to US$205.4 million in Q4 2025, while quarterly EPS has ranged from US$0.29 to US$1.00. This gives investors a clear view of how profitability tracks alongside top line...